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BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson’s disease therapy but often fail to improve
cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including
noradrenaline, which is linked to impulsivity and response inhibition. We therefore examined the effect of the
selective noradrenaline reuptake inhibitor atomoxetine on response inhibition in a stop-signal paradigm.
METHODS: This pharmacological functional magnetic resonance imaging study used a double-blinded randomized
crossover design with low-frequency inhibition trials distributed among frequent Go trials. Twenty-one patients
received 40 mg atomoxetine or placebo. Control subjects were tested on no-drug. The effects of disease and drug
on behavioral performance, regional brain activity, and functional connectivity were analyzed using general linear
models. Anatomical connectivity was examined using diffusion-weighted imaging.
RESULTS: Patients with Parkinson’s disease had longer stop-signal reaction times, less stop-related activation in
the right inferior frontal gyrus (RIFG), and weaker functional connectivity between the RIFG and striatum compared
with control subjects. Atomoxetine enhanced stop-related RIFG activation in proportion to disease severity. Although
there was no overall behavioral beneﬁt from atomoxetine, analyses of individual differences revealed that enhanced
response inhibition by atomoxetine was associated with increased RIFG activation and functional frontostriatal
connectivity. Improved performance was more likely in patients with higher structural frontostriatal connectivity.
CONCLUSIONS: This study suggests that enhanced prefrontal cortical activation and frontostriatal connectivity by
atomoxetine may improve response inhibition in Parkinson’s disease. These results point the way to new stratiﬁed
clinical trials of atomoxetine to treat impulsivity in selected patients with Parkinson’s disease.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2014.01.024Dopaminergic drugs remain the mainstay of Parkinson’s
disease (PD) therapy but often fail to improve cognitive and
behavioral problems such as impulsivity and poor executive
control (1–3). Their limited effect may be because they do not
address the loss of other monoaminergic projections to the
forebrain, including noradrenaline (4–6), or changes in the
frontostriatal connections that support inhibition and other
executive functions (7). Noradrenergic agents have been
suggested as a treatment for impulsivity and executive
dysfunction (8–11). This study focuses on one important facet
of the multidimensional construct of impulsivity, the impair-
ment in response inhibition.
We proposed that noradrenaline plays a crucial role in
regulating the neurocognitive systems for response inhibition
in the context of PD, based on preclinical evidence from
animal and human studies. We distinguished the prevention of
prepotent action (restraint) from stopping an initiated action
(cancellation). These two forms of response inhibition are
typically studied with the NoGo paradigm and stop-signal
reaction time (SSRT) task, respectively. In rats and humans,0 Crown Copyright & 2015 Published by Elsevier Inc on behalf of S
logical Psychiatry April 15, 2015; 77:740–748 www.sobp.org/journal
SEE COMMENTAthe selective noradrenaline reuptake inhibitor atomoxetine
improves stop-signal performance (12–16), reduces premature
decisions (17,18), and increases right inferior frontal gyrus
(RIFG) activation (19). In contrast, a similar dose of atom-
oxetine had no effect (or even negative impact) on NoGo
inhibition in healthy adults (20,21), which supports preclinical
evidence of a neuropharmacologic distinction between
restraint and cancellation type inhibition (22,23). Evidence for
a noradrenergic beneﬁt on stop-signal performance also
comes from human and animal studies of methylphenidate,
a reuptake inhibitor of both noradrenaline and dopamine (24–
28). The beneﬁcial effect of methylphenidate on SSRT might,
in principle, be due to either dopaminergic or noradrenergic
mechanisms alone, but noradrenergic and dopaminergic sys-
tems may also act synergistically (27), which is of particular
relevance to the possible use of noradrenergic drugs for
adjunctive treatment of PD.
Using pharmacological functional magnetic resonance
imaging (fMRI), we examined the effect of atomoxetine
(40 mg, versus placebo) on response inhibition in PD. Aociety of Biological Psychiatry.
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preliminary double-blinded randomized crossover behavioral
study (29). This study went further, using fMRI to reveal the
mechanisms of atomoxetine’s effect and identifying potential
predictors of treatment beneﬁt. We studied the impact of
atomoxetine on SSRT and NoGo inhibition, using a task
incorporating both NoGo and stop-signal trials.
We predicted 1) that action restraint (NoGo) and cancella-
tion (SSRT) are both impaired in PD (30,31); 2) that atom-
oxetine selectively enhances activations of the RIFG on
successful stop-signal trials; and 3) that the behavioral effects
of atomoxetine would depend not only on the stop-signal
RIFG activation but also on the RIFG-striatum connectivity that
links the inhibition with motor systems.
METHODS AND MATERIALS
Participants
Twenty-one patients with PD (United Kingdom PD Society
Brain Bank Clinical Diagnostic Criteria) (32,33) were recruited
via the Cambridge University PD Research Clinic. Inclusion
criteria were 1) Hoehn and Yahr Scale 1.5 to 3; 2) age 45 to 80;
3) English speaking; 4) right handed; and 5) nondemented
(clinical impression and Mini Mental State Examination .26/
30). Patients were excluded by 1) clinically signiﬁcant current
depression; and 2) contraindications to magnetic resonance
imaging (MRI) or atomoxetine. None of our patients had
impulse control disorders. All of them were tested on regular
PD medication, including levodopa (n = 19), nonergot do-
pamine agonists (n = 17; 8 pramipexole, 8 ropinirole, 1Table 1. Demographic and Clinical Features and Neuropsycho
Differences)
Features/Measures Parkinson
Male:Female 11
Age (Years) 64.0
Education (Years) 14.6
Mini Mental State Examination 28.9
Duration of Symptoms (Years) 10.8
UPDRS I: Mentation, Behavior and Mood 8.8
UPDRS III: Motor 20.6
Hoehn and Yahr Scale 1.9
Schwab and England Activities of Daily Living Scale 86.5
Levodopa Actual Dose (mg/day) 393.4
Levodopa Equivalent Dose (mg/day) 632.6
Beck Depression Inventory II 9.9
Epworth Sleep Scale 9.3
Insomnia Severity Index 9.2
REM Sleep Behaviour Disorder Screening Questionnaire 6.4
Spot-the-Word Test 112.8
Category Fluency Test 20.6
Letter Fluency Test 17.0
Forward Digit Span 7.0
Backward Digit Span 5.4
Simple Reaction Time (msec) 293.7
Choice Reaction Time (msec) 353.4
Group difference: p values of chi-squared or two-sample t tests as app
ns, not signiﬁcant; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
Biological Protigotine), and other antiparkinsonian medications (n = 8;
7 amantadine, 1 rasagiline, 1 selegiline). All patients were
tested in their “on” state. Levodopa equivalent dose (LED) was
calculated by the formula of Tomlinson et al. (34). Demo-
graphic and clinical features of participants are given in
Table 1.
Twenty healthy control subjects with no history of signiﬁ-
cant neurologic or psychiatric disorder were recruited from the
Cambridge University PD Research Clinic database and the
Cognition and Brain Sciences Unit volunteer panel. This study
was approved by the local research ethics committee and
exempted from clinical trials status by the Medicines and
Healthcare Products Regulatory Agency. Written informed
consent was obtained from all participants.
Experimental Design
A double-blinded randomized crossover design was used, with
separate sessions at least 6 days apart, including a neuro-
psychological battery and brain imaging, after either 40 mg oral
atomoxetine or an identically overcoated placebo capsule. In
humans, plasma concentration of atomoxetine peaks approx-
imately 2 hours after a single oral dose (35). Blood samples,
therefore, were collected 2 hours after administration, immedi-
ately before fMRI scanning in each session (plasma concen-
tration after atomoxetine: mean 444 ng/mL, range 32–889 ng/
mL; under placebo: 0 ng/mL). Control subjects underwent one
testing session only without drug or placebo.
The inhibition task included randomly interleaved action
restraint and cancellation trials, which were matched for drug
levels, practice effects, and fatigue. There were 360 Go trialslogical Measures (Means, Standard Deviations, and Group
’s Disease Control Subjects Group Difference
:10 12:8 ns
(8.1) 65.3 (5.7) ns
(3.8) 15.1 (2.5) ns
(1.2) 29.3 (.9) ns
(4.9) – –
(4.9) – –
(7.7) – –
(.4) – –
(5.9) – –
(221.0) – –
(310.6) – –
(5.5) 3.8 (3.9) p , .001
(5.3) 5.1 (2.9) p , .01
(5.8) 3.1 (2.8) p , .001
(2.9) 2.0 (1.5) p , .001
(13.6) 121.2 (10.3) p , .05
(4.9) 24.3 (6.7) p , .05
(5.6) 18.1 (4.5) ns
(1.1) 7.2 (.8) ns
(1.5) 5.7 (1.3) ns
(53.0) 314.4 (71.8) ns
(47.3) 392.2 (70.0) p , .05
ropriate (two-tailed; ns, p . .1).
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(17%). In Go trials, participants responded to a left/right black
arrow (duration 1000 msec) by pressing left/right buttons with
their right hand. In SS trials, the left/right black arrow changed
color (from black to red) concurrent with a tone, after a short
variable stop-signal delay, indicating the need to cancel the
response. The stop-signal delay was varied from trial to trial in
steps of 50 milliseconds by a tracking algorithm to maintain
50% successful inhibition (15). In NoGo trials, participants
were required to make no response to a red left/right arrow
(duration 1000 msec) and concurrent tone, equivalent to a
stop-signal delay of zero. Preliminary studies in 20 healthy
adults indicated that performances and activations were
preserved in the combined task compared with separate
NoGo and stop-signal tasks.
For this task, four key parameters of interest were mea-
sured: the rate of Go commission errors, mean reaction time of
correct Go trials (Go RT), rate of NoGo commission errors, and
SSRT. For Go trials, a commission error occurred when
participants mistakenly pressed the opposite buttons. For
NoGo trials, a commission error means participants pressed
a button. Both error rates were arcsine transformed for further
analysis. The SSRT was estimated by subtracting mean stop-
signal delay from ﬁnishing time of the stop process (using the
integration method) (36). The ﬁnishing time is the nth Go RT,
where Go RTs are rank-ordered and n is determined by the
probability of responding, p(respond|signal), and the number of
correct Go trials, m, as n 5 m 3 p(respond|signal). We also
monitored omission errors on Go trials. Patients showed
higher rates of Go omission errors than control subjects
(placebo 7%, atomoxetine 9%, control 4%, p , .01). Analysis
of the Go RT distribution indicated that omission errors were
not due to excessive response times but other impairments
(e.g., slipping off the buttons or failure to press the button).
Although the omissions can only be detected for Go trials,
their occurrence in SS trials may affect SSRT estimation, as
p(respond|signal) would be underestimated. The tracker algo-
rithm may also elevate the stop-signal delay. We corrected the
observed p(respond|signal) by individual subject’s Go omis-
sion rate using equation 1 below (written communication,
G. Logan, Ph.D., 2013). Correction of NoGo error rate used
equation 2.
Corrected pðrespondjsignalÞ 5 Observed pðrespondj
signalÞ= 12Go omission rateð Þ (1)
Corrected NoGo error rate 5 Observed NoGo error rate=
12Go omission rateð Þ (2)
Disease effects on behavioral indices were examined by two-
sample t tests (PD-placebo . control). To investigate drug
effects on SSRT and NoGo error rate, repeat-measures
analyses of variance were conducted with drug (atomoxetine
vs. placebo) as a within-subject factor and disease severity
(Uniﬁed Parkinson’s Disease Rating Scale [UPDRS] motor),
age, LED, and plasma concentration as covariates. Note that
the disease effect refers to treated Parkinson’s disease
(37,38). In principle, differences between PD-placebo and
control subjects could be due to the presence of PD, the
use of medication, or in our design, the additional use of a
placebo tablet in the PD-placebo group. However, the742 Biological Psychiatry April 15, 2015; 77:740–748 www.sobp.org/jconcurrent use of dopaminergic drugs is unlikely to fully
explain the group differences (30).
Participants also completed the Beck Depression Inventory
II, Epworth Sleepiness Scale, Insomnia Severity Index, REM
Sleep Behaviour Disorder questionnaire, Spot-the-Word test,
category and letter ﬂuency tests, forward and backward digit
spans, and simple and choice reaction times.
fMRI Data Acquisition and Analysis
Magnetic resonance imaging used a Siemens Trio 3T scanner
(Siemens, München, Germany). Functional images were
acquired using a quiet echo planar imaging sequence (2656-
msec repetition time, 44-msec echo time, 781 ﬂip angle, 32
sequential descending oblique axial slices, 192 3 192 mm2
ﬁeld of view, 3-mm thickness, .75-mm gap, and 3 3 3 mm2
in-plane resolution) (39). High-resolution T1-weighted mag-
netization-prepared rapid-acquired gradient echo images were
acquired (144 sequential sagittal slices, 240 3 240 mm2 ﬁeld
of view, 1.25-mm thickness, and 1.25 3 1.25 mm2 in-plane
resolution).
Functional MRI analysis used SPM8 (Functional Imaging
Laboratory, London, United Kingdom; www.ﬁl.ion.ucl.ac.uk/
spm). Eleven volumes were discarded to allow magnetization
equilibration. Functional images were realigned to the ﬁrst
image, sinc-interpolated to correct for differences in slice
acquisition time, and normalized to the Montreal Neurological
Institute (MNI) template using iterative segmentation. Normal-
ized images were spatially denoised using a wavelet-based
three-dimensional denoising approach, which not only sup-
presses noise but also preserves essential spatial details (edge
and shape of activation) that are often suppressed in Gaussian
smoothing (40).
A univariate analysis examined the effects of disease and
drug on activation. Subject-level general linear models con-
volved a design matrix with the canonical hemodynamic
response function. Event types included in the design matrix
were correct SS, NoGo, and Go trials and commission and
omission error trials. Six movement parameters were included
as nuisance regressors. Classical parameter estimation was
applied with a one-lag autoregressive model and high-pass
ﬁlter of 128 seconds. Contrasts of interest, SS . Go and
NoGo . Go, were entered into one-sample t tests for stop-
related and NoGo-related activations of each group (voxel-
level p , .001 uncorrected, cluster-level p , .05 familywise
error [FWE]-corrected).
In view of our anatomically constrained hypotheses regard-
ing disease and drug effects, a study-speciﬁc RIFG region of
interest (ROI) was built. This ROI is the intersection of the
anatomical RIFG (Automated Anatomical Labeling based
[Automated Anatomical Labeling, AAL, Caen University,
France]) and the stop-related (SS . Go) or NoGo-related
(NoGo . Go) activations in control subjects. Disease effects
on stop-related and NoGo-related RIFG activations were
examined by two-sample t tests with small volume correction
(PD-placebo , control, voxel-level p , .05 FWE-corrected). To
investigate drug effects, betas (parameter estimates) of the
RIFG ROI were pooled in repeated-measures analyses of
variance with drug as a within-subject factor and UPDRS
motor, age, LED, and plasma concentration as covariates.ournal
Table 2. Performance on the Stop-Signal and NoGo Tasks
Parameters
Control
Subjects PD-PLA PD-ATO
Disease
Effect
ATO Effect
(Whole Group)
SSRT (msec) 142 (44) 167 (50) 181 (85) p , .05 ns
Go RT (msec) 532 (129) 554 (108) 562 (104) ns ns
NoGo Error (rad) .06 (.13) .14 (.13) .13 (.15) p , .05 ns
Go Error (rad) .08 (.05) .14 (.06) .15 (.07) p , .001 ns
Values are group means (standard deviations). Disease effect refers
to the contrast PD-PLA vs. control subjects (two-sample t tests), which
differs by the presence of Parkinson’s disease and concurrent
dopaminergic/placebo medication in patients. ATO effect refers to
the contrast PD-ATO vs. PD-PLA (repeated-measures analyses of
variance with age, Uniﬁed Parkinson’s Disease Rating Scale, levodopa
equivalent dose, and plasma concentration as covariates). ns,
p . .1.
ATO, atomoxetine; ns, not signiﬁcant; PD, Parkinson’s disease;
PLA, placebo; rad, arcsin transformed to radians; RT, reaction time;
SSRT, stop-signal reaction time.
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interaction between the RIFG and striatum was modulated by
the disease and/or atomoxetine. Physiological fMRI signals
were extracted from a spherical RIFG ROI (unbiased ROI with
6-mm radius, centered at the RIFG peak of SS . Go in all
subjects, i.e., a one-sample t test combining control subjects
and patients) and included in another subject-level general
linear model (physiological regressor). Estimated betas indi-
cated the degree to which the time course of a voxel
correlated with the RIFG time course. One-sample t tests
showed regions positively correlated with the RIFG in each
group (voxel-level p , .001 uncorrected, cluster-level p , .05
FWE-corrected). The effects of disease (PD-placebo , control)
and drug (PD-atomoxetine . placebo) were examined by two-
sample and paired-sample t tests, respectively (small volume
correction, voxel-level p , .05 FWE-corrected).
Diffusion MRI
Diffusion-weighted images were collected along 63 gradient
directions (single acquisition, 63 sequential interleaved
ascending axial slices, 192 3 192 mm2 ﬁeld of view, 2-mm
thickness, and 2 3 2 mm2 in-plane resolution) and analyzed
with FSL4.1 (FMRIB software library, FMRIB, Oxford, United
Kingdom; www.fmrib.ox.ac.uk/fsl). Images were corrected for
head movements and eddy currents and smoothed with a 2.5-
mm Gaussian kernel. Diffusion tensors were linearly ﬁtted to
the diffusion-weighted images, and fractional anisotropy (FA)
images were calculated for tract-based spatial statistics (41).
The FA images were corrected for outlier values, registered to
the FMRIB58_FA template, and normalized to the MNI 152
space. A mean FA skeleton was derived and thresholded at FA
. .2 to represent the center of the white matter tracts common
to all subjects. Permutation tests with threshold-free cluster
enhancement (42) examined whether the effects of atom-
oxetine on SSRT varied with the strength of frontostriatal
connections. Based on our hypothesis of frontostriatal inter-
actions between inhibition and motor systems, we focused on
the right anterior internal capsule, which contains ﬁbers
connecting the frontal lobe, striatum, and thalamus (ROI based
on the Johns Hopkins University diffusion tensor imaging-
based white-matter atlas).RESULTS
Behavioral Results
Results of the neuropsychological battery are given in Table 1.
Groups were well matched by age, sex, education, and Mini
Mental State Examination. As is typical of PD, sleep and
depression symptom scores were higher and category
(semantic) ﬂuency was reduced in patients (33).
Table 2 shows the SSRT, Go RT, Go error rate, and NoGo
error rate in each group. Compared with control subjects, PD-
placebo had longer SSRT and more NoGo errors and Go
errors. The group difference in SSRT could not be attributed to
a difference in Go RT. Although there was no groupwise drug
effect, the behavioral beneﬁt of atomoxetine was conditional
on individual differences in brain activation and functional and
anatomical connectivity (see below).Biological PfMRI Results
Figure 1 presents inhibition-related activations, including the
RIFG, in each group. Control subjects showed RIFG activa-
tions for SS . Go (peak coordinates in MNI space [54 18 8],
t 5 7.17, 1621 voxels) and for NoGo . Go (peak [48 18 22],
t 5 6.00, 452 voxels; Figure 1A). The stop-related RIFG
activation (SS . Go), not the NoGo-related activation (NoGo
. Go), was signiﬁcantly reduced in PD-placebo compared
with control subjects (disease effect, peak [56 16 12], t 5 3.88,
14 voxels; Figure 1A).
The atomoxetine effect on stop-related RIFG activation
showed an interaction between drug and UPDRS motor (F 5
11.78, p , .005), as well as an interaction between drug and
age (F 5 12.56, p , .005). This indicates that atomoxetine
enhanced RIFG activations in more advanced disease and in
older patients (Figure 1B). There was no effect of LED or
plasma concentration in the multiple regression model (see
also Figure S2 in Supplement 1). No drug effect was obtained
on NoGo-related RIFG activation.
The NoGo and SSRT tasks are associated with widespread
activations beyond the RIFG (43,44). The RIFG is the focus of
this study, but we also analyzed the drug effects on other
areas including the left inferior frontal gyrus, supplementary
motor area, striatum, and thalamus. The results are presented
in the details in Supplement 1. In brief, we observed an effect
of atomoxetine in none of these areas except the thalamus
(Figure S1 in Supplement 1).
Figure 2A presents areas functionally correlated positively
with the RIFG, including the bilateral striatum. Control subjects
showed strong coupling between the RIFG and right striatum
(peak [20 8 8], t 5 9.16, 537 voxels). The interregional
interaction was signiﬁcantly reduced in PD-placebo compared
with control subjects (disease effect, peak [18 10 16], t 5 3.87,
13 voxels). Atomoxetine did not restore the frontostriatal
connectivity at the group level.
To determine whether change of behavioral performance
was related to atomoxetine’s enhancement of RIFG activity
and/or RIFG-striatum connectivity, a linear regression model
(equation 3) used the change of SSRT as a dependent variable
(ΔSSRT: SSRT-atomoxetine vs. SSRT-placebo). Independentsychiatry April 15, 2015; 77:740–748 www.sobp.org/journal 743
Figure 1. (A) Control subjects showed greater stop-related (stop-signal
[SS] . Go, warm colors) and NoGo-related activations (NoGo . Go, cool
colors) in the right inferior frontal gyrus (RIFG). The stop-related RIFG
activation was signiﬁcantly weaker in Parkinson’s disease-placebo (PD-
PLA) than in control subjects (disease effect, p , .05 small-volume
corrected). Color scales indicate t values. Coordinates are in Montreal
Neurological Institute space. (B) Atomoxetine selectively enhanced the
stop-related RIFG activation in more advanced disease (drug 3 severity)
and in older patients (drug 3 age). The atomoxetine-induced change of
RIFG activity (ΔActivity) was positively correlated with Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) and age (mean-corrected data).
Figure 2. (A) Control subjects showed strong functional coupling
between the right inferior frontal gyrus (RIFG) and striatum. The
RIFG-striatum connectivity was signiﬁcantly weaker in Parkinson’s disease-
placebo (PD-PLA) than in control subjects (disease effect, p , .05 small-
volume corrected). Color scales indicate t values. Coordinates are in
Montreal Neurological Institute space. (B) The atomoxetine-induced change
of stop-signal reaction time (SSRT) (ΔSSRT) was related not only to the
change of RIFG activity (ΔActivity, p , .05) but also to the change of RIFG-
striatum connectivity (ΔConnectivity, mean-corrected data, p , .005).
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(ΔActivity, activity betas from the study-speciﬁc RIFG ROI), the
change of RIFG-striatum connectivity (ΔConnectivity, connec-
tivity betas from the signiﬁcant cluster of right striatum in
control subjects), and the baseline SSRT under placebo
(SSRT-placebo).
ΔSSRT 5 β13ΔActivity1β23ΔConnectivity1β3
3SSRT2placebo (3)
The model was signiﬁcant overall (F 5 8.97, p 5 .001).
Figure 2B illustrates that ΔSSRT was related to both ΔActivity
(β1 5 2.37, t 5 22.14, p , .05) and ΔConnectivity (β2 5 2.63,
t 5 24.11, p 5 .001), in addition to the SSRT-placebo (β3 5
.61, t 5 3.49, p , .005). It suggests that the behavioral effect
of atomoxetine depends not only on changes in frontal activity
but also on changes in frontostriatal connectivity.
In addition to changes of functional connectivity, the
strength of structural connectivity between the frontal cortex
and striatum predicted atomoxetine’s effect on performance
(Figure 3). The SSRT change (ΔSSRT) was negatively corre-
lated with the fractional anisotropy of white matter in the744 Biological Psychiatry April 15, 2015; 77:740–748 www.sobp.org/janterior limb of the internal capsule: a reduction in SSRT was
observed in patients with greater anatomical frontostriatal
connectivity.
DISCUSSION
This study investigated effects of the selective noradrenaline
reuptake inhibitor atomoxetine on response inhibition in
patients with PD. We conﬁrmed that patients with PD and
on dopaminergic medication were impaired at response
inhibition, even in the absence of impulse control disorders,
with longer SSRT and more NoGo errors than healthy control
subjects. Behavioral impairments were associated with
reduced RIFG activations on successful stop-signal trials
and weaker functional connectivity between the RIFG and
striatum. The group differences might arise from the presence
of neuropathology or concurrent optimized motor therapy by
dopaminergic drugs. Atomoxetine modulated the stop-related
RIFG activation in PD, similar to its enhancement of RIFG
activation in another impulsive disorder, attention-deﬁcit/
hyperactivity disorder (ADHD) (11). Enhanced activation
emerged in patients with more severe disease. Moreover,
improvements in stop-signal performance correlated not only
with atomoxetine’s effect on frontal activation but also with its
effect on frontostriatal connectivity.
These observations build on studies of atomoxetine in
healthy adults and those with ADHD (15,19), conﬁrming that
noradrenaline plays an important role in regulating response
inhibition. However, we propose that enhancement of pre-
frontal activation is not sufﬁcient to improve behavioralournal
Figure 3. The behavioral beneﬁt of atomoxetine (reduction in stop-signal
reaction time, ΔSSRT) was related not only to the functional connectivity
but also to the structural connectivity between the frontal cortex and
striatum (fractional anisotropy [FA] of white matter, p , .05 threshold-free
cluster enhancement-corrected within anterior-internal capsule skeleton).
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also enhanced. This would explain why the behavioral beneﬁts
of atomoxetine were marked in healthy adults (19) with
intact corticostriatal connectivity but not at the group level
with PD or ADHD (11), where frontostriatal connectivity is
often impaired (7). Moreover, patients vary in their responses
to noradrenergic or other treatments. The effectiveness
of treatment may be predicted if impairments of regional
function and network communication are considered jointly,
including anatomical frontostriatal connectivity. Functional
and/or structural connectivity might therefore be used in the
stratiﬁcation of patients for treatment and in prediction of
efﬁcacy.
It might at ﬁrst seem paradoxical that atomoxetine
enhanced stop-related RIFG activation in patients with rela-
tively more advanced disease, while reducing SSRT in patients
with stronger pretreatment frontostriatal structural connectiv-
ity. However, these results are consistent. First, responses to
atomoxetine may be strongly inﬂuenced by the baseline
noradrenergic state. A Yerkes-Dodson model (of an inverted
U-shaped function) has been proposed to account for the
nonlinear relation between noradrenaline levels and task
performances in animal studies (45,46). In this model, the
performance is optimal with intermediate noradrenaline levels
but impaired at excess noradrenaline levels. In a previous
study of an independent PD cohort, we observed this patternBiological Pof responses to atomoxetine in PD: low plasma concentration
improved response inhibition, whereas high concentration
impaired response inhibition (29). We propose that our dose
of atomoxetine represents a replacement therapy for patients
who have lost a signiﬁcant proportion of noradrenergic
capacity (5). But for patients with mild disease and minor
changes in intrinsic noradrenaline transmission, the same
atomoxetine dose represents in effect an overdose. Second,
for atomoxetine to be able to exert a behavioral beneﬁt, the
RIFG must be effectively connected with the motor systems
that ultimately generate behavioral outputs. Because the
striatum modulates the execution of actions in response to
the cortical motor systems (47), the relative preservation of
frontostriatal connectivity improves the ability to relay inhi-
bition commands. It is worth noting that neither UPDRS nor
frontostriatal connectivity represents a gold standard bio-
marker for the stage of disease. While both would be expected
to change when disease progresses, they might not be driven
by the same biological factors. For example, UPDRS might be
higher in some patients because of signs that are not directly
related to the frontostriatal connectivity (e.g., tremor or
balance). In our cohort, UPDRS motor scores and diffusion
tensor imaging measures of frontostriatal connectivity were
not signiﬁcantly correlated.
Atomoxetine did not signiﬁcantly affect NoGo activation or
behavior. While this could be due to type II error, it is also
consistent with preclinical studies (20,21) reporting stop-signal
modulation by noradrenaline (15,19) and NoGo modulation by
serotonin (48). This neuropsychopharmacologic speciﬁcity
provides a reassuring internal control for the observed effects
of atomoxetine.
The role of noradrenaline extends beyond response inhi-
bition (8). Previous studies have linked the noradrenergic system
with other executive functions, such as cognitive ﬂexibility in
response to a changing environment (10). For example, atten-
tional set-shifting in the Wisconsin Card Sorting Test and
Cambridge Neuropsychological Test Automated Battery intra-
dimensional/extradimensional set-shifting task are impaired by
PD (49,50) and in animals with selective depletion of cortical
noradrenaline (51,52) but can be relieved by atomoxetine
(53,54). Noradrenergic systems may therefore support multiple
executive processes, including control of motor and nonmotor
impulsivity, response inhibition, and cognitive ﬂexibility (21,55),
which requires further evaluation for PD.
There are clinical, methodological, and pharmacologic lim-
itations with this study. First, our investigation was limited to
response inhibition rather than other dimensions of impulsivity,
such as reﬂection impulsivity or impairment of decisions based
on risk and rewards. The latter have been strongly associated
with dopaminergic dysfunction in treated PD (1–3). Second, we
relied on clinical diagnostic criteria because the United King-
dom PD Society Brain Bank Criteria have high sensitivity and
speciﬁcity. Clinically, none of our patients had impulse control
disorders (ICDs). But, we note that PD causes impulsivity and
response inhibition deﬁcits even without ICDs (30,31,56).
Further studies are needed to test whether atomoxetine can
improve impulsivity in patients with ICDs. Third, fMRI measures
a hemodynamic response to neural activity and in principle
atomoxetine might alter fMRI signals through affecting regional
cerebral blood ﬂow. However, the frontal regions and striatumsychiatry April 15, 2015; 77:740–748 www.sobp.org/journal 745
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cognitive and anatomical speciﬁcity of the effects we observed
make a signiﬁcant direct or generic effect of atomoxetine on
the neurovascular response unlikely.
Finally, we must consider the neuropharmacologic complexity
of patients and atomoxetine. Our data alone cannot determine
whether the effects of atomoxetine are via cortical reuptake
inhibition (most likely) (23,55), from changes in phasic-to-tonic
ﬁring ratios in the locus coeruleus (45), or through antagonism of
glutamate receptors (58). We recognize that atomoxetine can
increase extracellular dopamine levels (59) and our patients took
levodopa and/or dopamine agonists. But the atomoxetine effect
is unlikely mediated by indirect dopaminergic mechanisms. First,
as we have shown with multiple regression models, the atom-
oxetine effect on activation was independent of LED. Second,
the speciﬁc effect of dopamine on stop-signal inhibition is
unclear. Some studies of SSRT have used methylphenidate,
which increases extracellular levels of both dopamine and
noradrenaline, leaving it ambiguous as to whether dopamine
or noradrenaline is responsible for the beneﬁcial effect
(11,24,60,61). Studies that used more selective dopaminergic
agents, such as levodopa and dopamine transporter blocker,
have observed minor effects on SSRT, and patients with PD
have poor response inhibition both on and off medication
(12,30,55,62). The advent of more selective noradrenergic drugs
will further address these issues in the future.
In conclusion, the noradrenergic reuptake inhibitor atom-
oxetine can improve response inhibition in a subgroup of
patients, especially when it is associated with enhanced stop-
signal activation in the inferior frontal cortex (which is more
likely with relatively more advanced disease). The behavioral
measure or response inhibition efﬁcacy was improved (i.e.,
shorter SSRT) for patients in whom frontostriatal functional
connectivity was also enhanced by atomoxetine or in those
with relatively preserved frontostriatal structural connectivity.
These ﬁndings contribute to the broader understanding of the
importance of noradrenergic systems for executive functions
and point the way to new stratiﬁed clinical trials of noradre-
nergic therapies in selected patients with Parkinson’s disease.ACKNOWLEDGMENTS AND DISCLOSURES
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